Dudediligence.

Oruka Therapeutics, Inc

ORKANASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Net income, by quarter
−$28.6MSep ’24−$25.8MDec ’24−$21.0MMar ’25−$24.6MJun ’25−$30.3MSep ’25−$29.6MDec ’25−$31.8MMar ’26−$41.2MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$0.00$0.00$0.00none on filenone on file
Operating income−$19.3M−$10.6M−$7.3M−$88.1M−$122.1M
Net income−$19.3M−$9.9M−$5.3M−$83.7M−$105.4M
Operating cash flow−$18.8M−$10.9M−$5.0M−$57.8M−$88.2M
Free cash flow−$18.8M−$10.9M−$5.0M−$58.0M−$88.4M
Cash$53.4M$42.4M$37.4M$61.6M$46.9M
Debt$0.00$0.00$0.00none on filenone on file
Shares outstanding14.4M14.4M14.5M37.4M48.7M